TRIAL DETAIL
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Withdrawn |
|||
Phase: |
2 |
Start Date 01/01/2017 |
Age of Trial (yrs) 8.3 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor + MEK inhibitor |
|||
Strategy: |
Block KIT + Block related tumor signal paths |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
SARC029 |
|||
Sponsor: |
Sarcoma Aliance for Research through Collaboration |
|||
Patient Contact: |
SARC OFFICE
734-930-7600
SARC029@sarctrials.org |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
Detailed Description: Trametinib and pazopanib are independently approved for other cancers. Both drugs work to inhibit tumor development in different ways. Combining these drugs may lead to improved disease control. The purpose of this study is to evaluate the effect of the combination of both drugs on advanced gastrointestinal stromal tumors. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Palo Alto |
CA |
94304 |
USA |